Thus, we demonstrate that the generations of EMT and glutamine-dependent phenotypes are attributed to the loss of NDRG2 expression in metastatic tumors, and the gain of NDRG2 function can suppress metastatic tumor survival through the blockage of glutaminolysis. The gene discussed is NDRG2; the disease is metastatic neoplasm.